Maria Martínez‐Rebollar

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman et al. · The Lancet Infectious Diseases · 2015 · 142 citations · Full text

Hiv/aids Counselling, Human Retrovirus, Antiviral Drug Development +9

Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study

Alexy Inciarte, Ana González-Cordón, Jhon Rojas et al. · AIDS · 2020 · 132 citations · Full text

Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients†

Montserrat Laguno, Javier Murillas, Sergio Veloso et al. · Hepatology · 2008 · 111 citations

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz et al. · The Lancet HIV · 2021 · 106 citations · Full text

Tolerability of integrase inhibitors in a real-life setting

Judit Peñafiel, Elisa de Lazzari, Mireia Padilla et al. · Journal of Antimicrobial Chemotherapy · 2017 · 103 citations · Full text